Comparative Pharmacology
Head-to-head clinical analysis: INDO LEMMON versus RELAFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDO LEMMON versus RELAFEN.
INDO-LEMMON vs RELAFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammation, pain, and fever.
Nabumetone is a nonacidic nonsteroidal anti-inflammatory drug (NSAID) that is a prodrug, rapidly metabolized to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), which inhibits cyclooxygenase (COX) and thereby prostaglandin synthesis.
Oral: 25-50 mg 2-3 times daily. Maximum daily dose: 200 mg.
1000 mg orally once daily, or 500 mg twice daily. Maximum dose 2000 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life approximately 24 hours (range 20-30 hours), allowing once-daily dosing.
Renal excretion of unchanged drug and metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for approximately 40%.
Primarily renal (90% as metabolites, ~5% unchanged); biliary/fecal minor (<5%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)